Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell

Inclusion Criteria: * Subjects must be ≥ 18 years, willing and able to sign informed consent * Patients could have been transplanted for hematological disorder (malignant or non-malignant) excepted myelodysplastic syndromes patients and had received either a myeloablative or a reduced intensity conditioning. All sources of allogeneic stem cells are allowed. * Prolonged (\> 2 months) transfusion-dependent thrombocytopenia * Screenings mean platelet count≤ 20 x giga/L or screenings mean platelet count ≤ 50 x giga/L with a history of bleeding. * (ECOG) performance status of 0-2 * Adequate liver function * Serum creatinine ≤ 176.8 μmol/L * Bone marrow aspirate with cytogenetics within 6 days of the first dose of romiplostim * Written informed consent Exclusion Criteria: * Relapse/progression of hematological malignancy (marrow examination required) * Non-controlled acute and/or chronic graft versus host disease (GvHD) * Active or uncontrolled infections * Cardiac pathology - Thrombosis * Pregnancy or breast feeding * Received interleukin-11 (IL-11) within 4 weeks of screening or previously received any thrombopoietic growth factor * Patients on anticoagulant therapy * Receipt or planned receipt of Pegylated Granulocyte Colony Stimulating Factor (PEG-G-CSF), or Granulocyte macrophage-colony stimulating factor (GM-CSF) within 4 weeks of the first dose of investigational product * Subject not using adequate contraceptive precautions, in the judgment of the investigator * Sensitivity to any Escherichia coli-derived product * Inability to comply with study procedures. * Subject currently is enrolled in or has not yet completed 30 days since ending other investigational device or drug study * No medical insurance in the French Health system